HER-2 amplification is highly homogenous in gastric cancer

摘要: Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab). The potential benefit anti-Her-2 therapy currently investigated in several other HER-2-amplified cancers including gastric cancer. Although HER-2 amplification occurs more than 10% cancers, heterogeneity and overexpression could represent a major drawback therapy. To address applicability trastuzumab cancer, tissue microarray sections 166 adenocarcinomas 69 lymph node metastases were analyzed using Food Drug Administration-approved reagents immunohistochemistry fluorescence situ hybridization. was seen 27 (16%) adenocarcinomas. Amplification typically high level with 20 copies per tumor cell HER-2/centromere 17 ratio >3. associated intestinal phenotype but unrelated to survival, grading, pT, pN, or pM. Identical status found primary their matched metastases. Moreover, Topoisomerase IIalpha coamplification analysis 3 16 large from 8 Her-2-positive did not reveal any amplicon site. combination homogeneity its expression metastatic tumors argues possible therapeutic utility